2024-05-13 05:18:05 ET
Summary
- Intellia's longstanding collaboration with Regeneron is important in its value proposition.
- With three cutting-edge late-stage programs, NTLA is among the top tier of gene editing companies.
- Solid financials underpin the Company.
- Intellia presents special risks.
This is my first Intellia Therapeutics article (NTLA). Intellia is a clinical stage gene editing company. It reported its Q1, 2024 earnings premarket on 05/09/2024 issuing its earnings press release (the " RELEASE ") conference call (the " CALL ") and 10-Q (the " 10-Q "). In addition to the foregoing referenced sources, this article will cite its 05/2024 Corporate Overview slide presentation (the " PRESENTATION ")....
Read the full article on Seeking Alpha
For further details see:
Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies